PAI-1 (Type-1 Plasminogen Activator Inhibitor), human
|Antibody||Host||Catalogue No.||Size||Product Insert|
|purified IgG||Sheep||SAPAI-IG||10 mg|
|peroxidase conjugated IgG||Sheep||SAPAI-HRP||0.2 mg|
Description of PAI-1 (Type-1 Plasminogen Activator Inhibitor)
Type I plasminogen activator inhibitor, PAI-1, is a 50 kDa single-chain glycoprotein which belongs to the serine protease inhibitor (SERPIN) family of proteins. The concentration of PAI-1 in normal human plasma is very low, with an average concentration of approximately 20 ng/ml. The plasma concentrations of PAI-1 can be affected by a number of factors including diurnal variations, age, sex, pregnancy, obesity and exercise status. PAI-1 is synthesized by various cell types including endothelial cells, hepatocytes, vascular smooth muscle cells, fibroblasts, mesothelial cells, granulosa cells and malignant cell lines. It is also found in the Ã¯ÂÂ¡-granules of platelets as well as plasma. PAI-1 exists in at least three different conformations, including an active form with a half-life of approximately 1 Ã¢â‚¬â€œ 3 hours, a latent form and a proteolytically or oxidatively inactivated form. The plasma glycoprotein vitronectin has been shown to bind active PAI-1 and stabilize it in its active conformation, extending its functional half-life to greater than 24 hours. Little specific binding of the latent or inactive forms of PAI-1 to vitronectin occurs. PAI-1 is considered to be the primary regulator of plasminogen activation in vivo. It is the major physiologic inhibitor of both the single chain and two-chain forms of tPA, being able to inhibit the single-chain form at least 10000 times greater than other PAIs.1-3
1. Kruithof, E.K.O. Plasminogen activator inhibitor type 1: biochemical, biological and clinical aspects. Fibrinolysis, 2:59-70, 1988.
2. Edelberg, J.M, Sane, D.C., and Pizzo, S.V. Vascular regulation of plasminogen activator inhibitor-1 activity. Semin. Thromb. Hemost., 20(4):319-323, 1994.
3. Loskutoff, D.J., Sawdey, M., and Mimuro, J. Type 1 plasminogen activator inhibitor, Prog. Thromb. Haemost., 9:87-115, 1988.
SAPAI-HRP Sheep anti-human PAI-1, IgG peroxidase
PAI-DP Human plasma deficient in PAI-1, immune depeleted, Frozen
PAI-LDP Human plasma deficient in PAI-1, immune depleted, Lyophilized
tPA/PAI-DP Human plasma deficient in both tPA/PAI-1, immune depleted, Frozen